Vienna, 02.06.2022. Headquartered in Vienna, Austria, the AOP Health Group laid the foundation for its expansion into the US market in the summer of 2021. The pharmaceutical company, which specializes in therapies for rare diseases and intensive care, signed a licensing agreement for the beta blocker Landiolol with Eagle Pharmaceuticals, a fully integrated pharmaceutical company based in New Jersey, USA, in August 2021.
Key milestone for Austrian pharmaceuticals company
Now, the AOP Health Group has taken the next step in its expansion plans by submitting the product to the U.S. Food and Drug Administration for approval. Agnes Kohl, Chief Business Officer at AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group, commented: “Expansion into the USA is an important strategic milestone for the Group. We have found the ideal partner in Eagle Pharmaceuticals, a company with extensive experience in the field of intensive care medicine. Eagle will handle marketing and distribution in the US after the approval process has been completed.”
Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals, Inc., said: “We are delighted that the new drug application was submitted to the FDA so soon after signing the licensing agreement. Landiolol is an excellent addition to our portfolio, with a great deal of potential in the USA, and we look forward to marketing this important therapeutic, if approved.”
Landiolol is an ultra short acting, cardio-selective, beta 1 blocker, which is used for the rapid heart rate control in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter with minimal effects on cardiac contractility (inotropy) and blood pressure. It was developed by the AOP Health Group and has been registered in several European countries since 2016 for the treatment of tachycardic supraventricular arrhythmias (irregular heart rates in the atrium) and non-compensatory sinus tachycardia (abnormally fast heart rates).